Supernus announces SPN-820 trial misses primary endpoint
Supernus (SUPN) announced that the Phase 2b study of SPN-820 in adults with treatment-resistant depression did not demonstrate a statistically ...
BioSpace2d
Supernus Falls Back on CNS Portfolio as Depression Drug Fails Mid-Stage Study
After SPN-820's failure, Supernus is relying on its non-stimulant ADHD drug Qelbree and the recently approved Parkinson’s ...
GlobalData on MSN3d
Supernus’s stock sinks after depression drug fails trial
Supernus Pharmaceutical’s stock declined following the release of disappointing Phase IIb trial results for SPN-820, an ...
Supernus plunges as mid-stage trial for depression therapy fails
Supernus Pharmaceuticals (NASDAQ:SUPN) lost ~20% in the premarket on Wednesday after the neuro-focused biopharma said its ...
FierceBiotech3d
Options shrink for Supernus depression drug candidate after key trial failure
Supernus Pharmaceuticals may have had a potential path forward for its depression drug candidate cut off after the asset ...
Nasdaq3d
Supernus Plunges On Failed Phase 2b Study Of SPN-820 In Treatment-resistant Depression
(RTTNews) - Shares of Supernus Pharmaceuticals Inc. (SUPN) are down over 20% in premarket trading Wednesday, following disappointing results from a Phase 2b study of SPN-820 in adults with ...
Supernus Pharmaceuticals Stock Falls On Disappointing Data From Treatment-Resistant Depression Trial
Supernus' SPN-820 Phase 2b study in treatment-resistant depression failed to meet its primary endpoint, prompting further ...
pharmaphorum3d
Supernus reports less than super data for depression drug
Faster-acting drugs have long been sought to protect people with severe depression who may be at risk of self-harm or suicide ...
BioWorld2d
Supernus phase IIb results drag down the stock
The phase IIb study results of Supernus Pharmaceuticals Inc.’s SPN-820 in treatment-resistant depression had pulled the company’s stock (NASDAQ:SUPN) down 15.6% on Feb. 19. The randomized, ...
MedPage Today on MSN3d
New APA President-Elect; Novel Depression Drug Flops; Probiotics and Schizophrenia
Investigational drug SPN-820, which activates the mTORC1 pathway, failed to significantly reduce depressive symptoms compared ...
Supernus Announces Topline Results from Phase 2b Study in Adults with Treatment Resistant Depression
Study did not demonstrate statistically significant improvement on primary endpoint of reduction in depressive symptoms as measured by MADRS ...